Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Log in

Sanda, Martin

Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
A Methylation Panel for Bladder Cancer	Involved	0	0
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge	Involved	0	0
EDRN Pre-Validation of Multiplex Biomarker in Urine	Involved	2	0
Prediction Rules Combining PHI with Urinary RNA Testing for Aggressive Prostate Cancer Detection	Leading	0	0
Prediction rules for aggressive prostate cancer in AS population	Leading	2	0
Upgrading Reference Set	Involved	0	0
URS Reference Set-Sanda (2025)	Leading	0	0

Closed Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement	Involved	28	0
EDRN Resource Network Exchange	Involved	0	0
Methylation & Proteomics-Based Detection of Bladder Cancer	Involved	0	0
PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014)	Leading	2	0
PCA3 Validation Study and Urinary Reference Set	Involved	2	0
Prostate Rapid Pre-Validation Set	Leading	6	0
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008)	Involved	2	0
Prostate Upgrading Team Project	Involved	0	0
Standard Specimen Reference Set: Prostate	Leading	0	0

Publications

Publication Name	PubMed ID	Journal
[Value of erythrocyte ferritin in heterozygous A2 and F thalassemias].	3660184	Sangre (Barc)
CD8<sup>+</sup> T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.	36580918
Covariate adjustment in continuous biomarker assessment.	34811731
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.	38635241
Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis.	38067373
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.	38814624	JAMA
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance.	39666350	JAMA Oncol
The diagnostic challenges of differentiating metastatic extramammary Paget disease and prostatic adenocarcinoma: A case report and review of the literature.	39553440	Urol Case Rep

Interests

Prostate Cancer Biomarkers: I conduct research in discovery, development and validation of multi-omic biomarkers to detect prostate cancer and classify aggresiveness

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site: Emory University
Degree(s): M.D.
Email: martinsanda@emory.edu
Person ID: 5469
EDRN Title: EDRN Principal Investigator
Note: To update contact information, please visit the Data Management and Coordinating Center .